6533b85cfe1ef96bd12bc181

RESEARCH PRODUCT

Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020

Ana M Cebrián-cuencaCarlos Brotons CuixartVicente Gil GuillénJorge Navarro PérezDomingo Orozco-beltránJosé R. BanegasEnrique Martín RioboóJosé Juan Alemán Sánchez

subject

medicine.medical_specialtyFamily medicineMedicina:Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings]030204 cardiovascular system & hematologyPharmacological treatment:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings]03 medical and health sciences0302 clinical medicineDiabetes mellitusDiabetes mellitusEpidemiologymedicine030212 general & internal medicineIntensive care medicine:Diseases::Cardiovascular Diseases [Medical Subject Headings]lcsh:R5-920:Diseases::Endocrine System Diseases::Diabetes Mellitus [Medical Subject Headings]business.industryMedicina de familia:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Atrial fibrillationGeneral MedicineAtención primariamedicine.diseasePrimary careCardiovasculardiseasesHealth promotionCardiovascular diseases:Health Care::Health Care Facilities Manpower and Services::Health Promotion [Medical Subject Headings]Preventive activitiesEnfermedades cardiovasculareslcsh:Medicine (General)Family PracticebusinessDyslipidemia

description

The recommendations of the semFYC's Program for Preventive Activities and Health Promotion (PAPPS) for the prevention of cardiovascular diseases (CVD) are presented. The following sections are included: Epidemiological review, where the current morbidity and mortality of CVD in Spain and its evolution as well as the main risk factors are described; Cardiovascular (CV) risk tables and recommendations for the calculation of CV risk; Main risk factors such as arterial hypertension, dyslipidemia and diabetes mellitus, describing the method for their diagnosis, therapeutic objectives and recommendations for lifestyle measures and pharmacological treatment; Indications for antiplatelet therapy, and recommendations for screening of atrial fibrillation. The quality of testing and the strength of the recommendation are included in the main recommendations.

10.1016/j.aprim.2020.08.002http://hdl.handle.net/10486/696043